Translational Medicine Market Analysis and Reports | USA Conference Series

Market Analysis - Translational Medicine 2017

Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative; "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community

Science Translational Medicine publishes articles containing original, science-based research that report successful progress toward improvements in clinical medicine Included within the scope are a broad array of traditional medical specialties including (but not limited to) cardiovascular medicine, cancer, immunology, neurology, psychiatry, metabolic diseases, radiology and imaging. Approaches applicable to all stages of the translational process are appropriate: bioengineering, drug discovery, diagnostics, biomarkers, pharmacokinetics, drug delivery, gene therapy and regenerative medicine.

Worldwide growth event has expanded from 12.7 million new cases in 2008 to 14.1 million in 2012, and it is normal that the rate will ascend by around 70% throughout the next two decades.

The National Centre for Advancing Translational Sciences (NCATS) at the National  Institutes of Health (NIH). NCATS involves incorporation of 5 existing programs that have a $720 million annual budget. NCATS was formed in order to focus on the development of innovative strategies to overcome identified bottlenecks in new drug development that currently take 13 years and cost over $1 billion dollars. The current approach relies on NIH-funded scientists to make basic science discoveries and compliment industries efforts to develop and capitalize on new therapies.

More recently, the Medical Research Council (MRC), UK in the year 2007 came out with Guidelines for accelerating the translation of Medical Research. Approximately 50 members of MRC’s community including industry and representatives from the Health Departments came together in February 2007 to discuss these issues. Delegates discussed the translational research process, MRC’s role and what more MRC could do.

Major Associations and Societies

  • Association for Clinical and Translational Sciences
  • International Society for Cardiovascular Translational Research
  • Central Society for Clinical and Translational Research
  • European Society for Translational Medicine
  • CHI Institute for Research and Innovation( Centre for Translational Research)
  • Johns Hopkins Institute for clinical and Translational Research    

 

                                                                                                

The Catholic Health Initiatives (CHI) Centre for Translational Research (CTR) provides fully consented bio specimens and clinical data to researchers, facilitating the development of next-generation drugs, diagnostics and devices. Our state-of-the-art research facility and biorepository, coupled with our 100+ hospital network and three academic medical centres, is here to support your discovery, preclinical and product development programs.

Translational Research Market

The UK has one of the excellent translational medicine (TM) systems in EU. Two types of biomedical research centres are playing critical roles for advancement of Translational research in the country i.e., Comprehensive BRCs and Specialist BRCs. These centres have boasted translation research in the country which is evident by increase in total number of clinical trials numbers i.e., 290 in 2005; have risen to more than 850 in 2009- 10.

Seventh Framework Program is a main source for research funding in EU, with a total budget of over € 50 billion (2007-2013), of which 12% was for health. FP7 gives an emphasis to projects related to translational research in infectious diseases, cancer, cardiovascular disease, diabetes/ obesity, and rare diseases.

Translational medicine is an emerging field in Austria. In the past few years, academics have undertaken initiatives for establishment of translational research infrastructure in Austria. The Austrian Science Fund (FWF) which is one of the main research funding bodies in Austria has started a translational Research Programme which is part of the BRIDGE Initiative, commissioned by the Federal Ministry for Transport, Innovation and Technology (BMVIT)

The National   Centre for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS is the vision of NIH director Francis S. Collins and involves incorporation of 5 existing programs that have a $720 million annual budget. NCATS was formed in order to focus on the development of innovative strategies to overcome identified bottlenecks in new drug development that currently take 13 years, have a >95% failure rate, and cost over $1 billion dollars.

South Korea has a translational education focus on meeting its demand for clinical trial educational demands. The government formed Korea National Enterprise for Clinical Trials (KoNECT) which has been operating nationwide education programs for clinical trial professionals since 2008 mainly through government funds.